{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:28:44Z","timestamp":1774438124932,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is a need for the development of therapies to delay cancer progression and prolong survival after initial chemotherapy for the treatment of small cell lung cancer (SCLC). Since apatinib has been found to exert promising effects on cancer patients after standard first\u2010line chemotherapy, this study aimed to investigate apatinib as a maintenance treatment following first\u2010line chemotherapy in extensive disease (ED)\u2010SCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The primary endpoints were overall survival (OS) and progression\u2010free survival (PFS). The secondary endpoints included toxicity and safety. Apatinib (250\u2009mg\/day) was administered during the chemotherapy interval and as maintenance therapy after 4\u20136\u00a0cycles until the patient's disease progressed, the patient died, or became intolerant to the drug's toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The patients who received apatinib maintenance treatment had a median PFS of 3.7\u00a0months (95% CI: 1.3\u20136.2\u00a0months). The median OS was 16.3\u00a0months (95% CI: 9.7\u201322.8\u00a0months). The objective response rate and disease control rate were 50.0% and 66.7%, respectively. Two patients required dose reduction due to adverse effects (AEs). The most common AEs included hypertension (<jats:italic>n<\/jats:italic>\u00a0=\u00a04, 33.3%) and hand\u2010foot\u2010skin reaction (<jats:italic>n<\/jats:italic>\u00a0=\u00a02, 16.7%). One patient developed diarrhea, while another patient developed hemoptysis. The most serious AE was intestinal obstruction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Apatinib maintenance therapy showed promising efficacy and safety to extend the OS\/PFS of patients with ED\u2010SCLC, thus making it a potent therapeutic option in future clinical practice. Given the small sample size of this study, further studies with large sample sizes are needed to validate the findings of the present study.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.14298","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T08:40:01Z","timestamp":1642149601000},"page":"557-562","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Apatinib as maintenance therapy following standard first\u2010line chemotherapy in extensive disease small cell lung cancer: A phase <scp>II<\/scp> single\u2010arm trial"],"prefix":"10.1111","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-4288","authenticated-orcid":false,"given":"Fei","family":"Teng","sequence":"first","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puyuan","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Hospital of Huanxing ChaoYang District Beijing  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Hospital of Huanxing ChaoYang District Beijing  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongqiu","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Hospital of Huanxing ChaoYang District Beijing  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-325X","authenticated-orcid":false,"given":"Junling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"issue":"3","key":"e_1_2_6_2_1","first-page":"192","article-title":"Advances in the treatment of relapsed small cell lung cancer","volume":"20","author":"Liu B","year":"2017","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"4","key":"e_1_2_6_3_1","first-page":"S26","article-title":"New drugs in small cell lung cancer","volume":"1","author":"Thatcher N","year":"2002","journal-title":"Suppl Tumori"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1061"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.553185"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37263"},{"key":"e_1_2_6_7_1","first-page":"2367","article-title":"Survival in small cell lung cancer is independent of tumor expression of VEGF and COX\u20102","volume":"24","author":"Rha JED","year":"2004","journal-title":"Anticancer Res"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7545"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6923"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.3423"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4844"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.3105"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.137"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.465"},{"key":"e_1_2_6_15_1","unstructured":"Chinese Clinical Oncology"},{"key":"e_1_2_6_16_1","unstructured":"Chinese Journal of Oncology"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30349-8"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.8585"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2764-8"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605668"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.009.10330"},{"issue":"3","key":"e_1_2_6_23_1","first-page":"701","article-title":"CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non\u2010small cell lung cancer","volume":"25","author":"Cui F","year":"2011","journal-title":"Oncol Rep"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01144.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12045"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.04.004"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.007"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.981526"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01939.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0111"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-7940(02)00112-4"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp200"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.3083"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.965"},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","unstructured":"Yutao LiuXH ZhouS.(2017)P3.04\u2013007 \u2010 a prospective study of Apatinib in advanced small cell lung cancer patients failed from two or more lines of chemotherapy. AbstractWCLC.","DOI":"10.1016\/j.jtho.2017.09.1665"},{"issue":"9","key":"e_1_2_6_36_1","first-page":"1880","article-title":"Effect of apatinib on the advanced non\u2010small cell lung cancer","volume":"37","author":"SHI Mingwei WS","year":"2017","journal-title":"J Clin Pathol Res"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-013-0257-x"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70311-0"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds145"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr128"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14298","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.14298","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T02:33:32Z","timestamp":1693103612000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.14298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/1759-7714.14298"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.14298","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"assertion":[{"value":"2021-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}